<DOC>
	<DOCNO>NCT02098473</DOCNO>
	<brief_summary>The purpose study determine effective dose ( ) RPC4046 treatment Eosinophilic Esophagitis ( EoE ) . This trial consist two phase : 16 week double-blind treatment 52 week open-label extension .</brief_summary>
	<brief_title>Dose Ranging Study RPC4046 Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>Histologic evidence EoE Clinical symptom EoE include dysphagia Primary cause esophageal eosinophilia EoE</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>